Aspira Pathlab

Who are in the management team of Aspira Pathlab?

As of March 2021, the management team of Aspira Pathlab includes Pankaj Jashwant Shah (Managing Director & CEO), Haseeb Drabu (Chairman), and several directors, including independent and executive members. Key roles are filled by Arvind Karsandas Bhanushali, Mangala Radha Krishnan Prabhu, Nikunj Mange, Subhash Raghunath Salunke, A C Mahajan, and Priya Pandey (Company Secretary).

As of March 2021, the management team of Aspira Pathlab includes:<BR><BR>1. Pankaj Jashwant Shah - Managing Director & CEO<BR>2. Arvind Karsandas Bhanushali - Executive Director<BR>3. Arvind Karsandas Bhanushali - Non Executive Director<BR>4. Mangala Radha Krishnan Prabhu - Independent Director<BR>5. Haseeb Drabu - Chairman<BR>6. Nikunj Mange - Director<BR>7. Subhash Raghunath Salunke - Independent Director<BR>8. A C Mahajan - Independent Director<BR>9. Priya Pandey - Company Secretary<BR><BR>Each member plays a significant role in the governance and management of the company.

When is the next results date for Aspira Pathlab?

No Upcoming Board Meetings

Has Aspira Pathlab declared dividend?

No Dividend History Available

Who are the peers of the Aspira Pathlab?

Aspira Pathlab's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Aspira Pathlab leads in 1-year returns at 80.64%, while Syngene Intl. has the lowest return at -3.47%.

Peers: The peers of Aspira Pathlab are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., N G Industries, Deccan Healthcar, Centenial Surgic, Bandaram Pharma, and Tejnaksh Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average management risk. Growth is Excellent at Bandaram Pharma, Average at Poly Medicure, Indegene, and the rest, while Below Average growth is seen at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Aspira Pathlab, N G Industries, Deccan Healthcar, Centenial Surgic, and Tejnaksh Health. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Vijaya Diagnost., while Good capital structure is noted at N G Industries, Deccan Healthcar, Centenial Surgic, and the rest have Average or Below Average.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 80.64%, while the lowest is Syngene Intl. at -3.47%. Aspira Pathlab's 1-year return is significantly higher than all its peers. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Deccan Healthcar, and Tejnaksh Health.

Is Aspira Pathlab overvalued or undervalued?

As of May 19, 2025, Aspira Pathlab is considered very attractive due to its strong performance metrics, including a PE ratio of 27.85 and a PEG ratio of 0.16, indicating it is undervalued compared to peers like Dr. Lal PathLabs and Metropolis Healthcare, despite recent underperformance against the Sensex, with a notable 107.67% return over the past year.

As of 19 May 2025, the valuation grade for Aspira Pathlab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently undervalued based on its strong performance metrics. Key ratios include a PE ratio of 27.85, an EV to EBITDA of 16.26, and a PEG ratio of 0.16, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Aspira Pathlab's valuation stands out, particularly against companies like Dr. Lal PathLabs, which has a PE ratio of approximately 40, and Metropolis Healthcare, with an EV to EBITDA of around 25. The robust ROCE of 18.34% and ROE of 18.63% further reinforce the company's strong operational efficiency. While the stock has underperformed the Sensex in shorter time frames, its impressive 107.67% return over the past year highlights its potential for growth, supporting the conclusion that Aspira Pathlab is currently undervalued.

What is the technical trend for Aspira Pathlab?

As of April 2, 2025, Aspira Pathlab's trend is mildly bullish, with mixed signals from key indicators like MACD and Bollinger Bands across different time frames.

As of 2 April 2025, the technical trend for Aspira Pathlab has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating some weakness in momentum. The daily moving averages are mildly bullish, suggesting short-term support. The Bollinger Bands show a mildly bearish stance on the weekly chart but bullish on the monthly, indicating mixed signals across time frames. The KST is bearish weekly but bullish monthly, adding to the complexity of the trend. Overall, the current stance is mildly bullish, with key indicators highlighting mixed momentum and trend signals across different time frames.

What does Aspira Pathlab do?

Aspira Pathlab & Diagnostics Ltd is a micro-cap pathology specialist established in 1973, reporting net sales of 58 Cr and a net profit of 7 Cr for the quarter ending March 2025. The company has a market cap of INR 54 Cr and key metrics include a P/E of 26.00 and a return on equity of 18.63%.

Overview: <BR>Aspira Pathlab & Diagnostics Ltd is a leading pathology specialist in the healthcare services industry, operating within the micro-cap market.<BR><BR>History: <BR>Incorporated in July 1973, Aspira Pathlab & Diagnostics Ltd has established itself as a prominent player in the pathology sector. The latest financial results reported are for the quarter ending March 2025, showcasing the company's ongoing operations.<BR><BR>Financial Snapshot: <BR>Net Sales: 58 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 18.63% <BR>Price to Book: 4.86 <BR><BR>Contact Details: <BR>Address: Flat No. 2 RD Shah Building, Shraddanand Road Ghatkopar(W) Mumbai Maharashtra : 400086 <BR>Tel: 91-22-71975756/5656 <BR>Email: info@aspiradiagnostics.com/urkalsoa <BR>Website: http://www.aspiradiagnostics.com

Who are the top shareholders of the Aspira Pathlab?

The top shareholders of Aspira Pathlab are Deepali Arvind Bhanushali with 8.6% and Rinku Vinod Bhanushali with 8.1%. Individual investors own 60.46% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Aspira Pathlab include Deepali Arvind Bhanushali, who holds the highest promoter stake at 8.6%. Following her, the highest public shareholder is Rinku Vinod Bhanushali, with a holding of 8.1%. Additionally, individual investors collectively own a significant portion of the company, accounting for 60.46% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Aspira Pathlab?

As of 24th July, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 61.00 Cr, with recent net sales of 22.01 Cr and a net profit of 2.03 Cr. Shareholder's funds are 10.14 Cr and total assets amount to 14.71 Cr as of March 2024.

As of 24th July, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 61.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 22.01 Cr and a Net Profit of 2.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 10.14 Cr and Total Assets of 14.71 Cr.

Are Aspira Pathlab latest results good or bad?

Aspira Pathlab's latest results are generally positive, with a Profit After Tax of Rs 1.10 crore, up 344.44% year-on-year, and net sales growth of 30.38%. However, the slowdown in sales growth from previous periods has led to a 'Hold' rating from MarketsMOJO, indicating a cautious outlook.

Aspira Pathlab's latest results show a mixed but generally positive performance. For the quarter ending June 2025, the company reported a Profit After Tax (PAT) of Rs 1.10 crore, which represents a remarkable year-on-year growth of 344.44%. This is a significant improvement compared to the Rs 0.85 crore PAT from the previous twelve-month period.<BR><BR>Additionally, net sales for the same six-month period reached Rs 11.03 crore, reflecting a year-on-year growth of 30.38%. However, it's worth noting that while the consolidated net profit showed an impressive growth of 740% compared to the previous year, the net sales growth rate has decreased from 78.46% in June 2024 to 13.15% in June 2025, indicating a slowdown in sales growth.<BR><BR>Overall, while Aspira Pathlab has achieved substantial growth in profit, the decline in sales growth rate may raise some concerns. MarketsMOJO has assigned a 'Hold' rating, suggesting a cautious outlook on the stock amidst these developments.

How has been the historical performance of Aspira Pathlab?

Aspira Pathlab's financial performance improved significantly from March 2024 to March 2025, with net sales rising to 22.00 Cr from 13.20 Cr, and a turnaround from losses to a profit after tax of 2.02 Cr. Key metrics such as EPS and operating profit margin also showed positive growth, indicating a strengthened financial position.

Answer:<BR>Aspira Pathlab has shown significant improvement in its financial performance from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in the previous year. Total operating income also rose to 22.00 Cr from 13.20 Cr, while total expenditure increased to 18.83 Cr from 14.76 Cr. This led to an operating profit (PBDIT) of 3.56 Cr, a recovery from a loss of 1.14 Cr in the prior year. Profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, resulting in a profit after tax of 2.02 Cr compared to a loss of 2.67 Cr previously. The earnings per share (EPS) turned positive at 1.96, up from a negative 2.59. The operating profit margin also saw a significant turnaround, reaching 14.41% from -11.82%, while the profit after tax margin improved to 9.18% from -20.23%. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with total liabilities rising to 17.46 Cr from 14.71 Cr. The book value per share improved to 7.03 from 5.07, indicating a strengthening financial position. Cash flow from operating activities remained stable at 1.00 Cr, with a closing cash equivalent of 1.00 Cr, up from none in the previous year.

Should I buy, sell or hold Aspira Pathlab?

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 31-Jan, Aspira Pathlab & Diagnostics Ltd's stock price is at 63.70, showing a slight rise but has underperformed recently with declines over the past week and month. Despite this, positive financial indicators and increasing investor interest suggest potential for future growth.

As of 31-Jan, Aspira Pathlab & Diagnostics Ltd's stock price is experiencing a slight rise, currently at 63.70, with a change of 0.03 (0.05%) upward. Despite this minor increase, the stock has underperformed in the short term, with a decline of 1.53% over the past week and 6.60% over the past month. Year-to-date, the stock has decreased by 3.75%, and over the past year, it has fallen by 17.27%, contrasting sharply with the Sensex, which has gained 7.18% during the same period.<BR><BR>However, there are positive indicators that suggest potential for future growth. The company has reported significant improvements in its financial performance, including a net profit growth of 85.86% and an operating profit growth rate of 32.87%. The operating cash flow is at its highest, and the return on capital employed (ROCE) is also at a strong level of 21.54%. Additionally, the stock is trading at a discount compared to its peers, with a very attractive valuation reflected in a price-to-book value of 4.5.<BR><BR>Investor participation appears to be increasing, as evidenced by a 171.06% rise in delivery volume on January 29 compared to the 5-day average. This suggests that while the stock has faced recent declines, there is growing interest among investors, which could support its price in the future. Overall, while the stock has faced downward pressure recently, the underlying financial health and increasing investor participation may contribute to a more favorable outlook moving forward.

Which are the latest news on Aspira Pathlab?